

Amendments to the Specification

Please replace the paragraph at page 9, lines 3-14, with the following amended paragraph:

A number of suitable NK₂ receptor antagonists are currently in clinical trials for other indications. These include, without limitation: SR 48968 or saredutant (((S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide) (CAS No. 142001-63-6), which is available from Sanofi-Synthelabo; and MEN 10627 (cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2 beta-5 beta)) (Quartara et al., "A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627," *Regul. Pept.* 65(1):55-59 (1996); Caciagli et al., "Large-scale production of peptides using the solid-phase continuous flow method. Preparative synthesis of the novel tachykinin antagonist MEN 10627," *J. Pept. Sci.* 3(3):224-230 (1997), which are hereby incorporated by reference in their entirety), which is available from Menarini Group, as well as pharmaceutically acceptable salts thereof. Suitable salts can be prepared according to known techniques. Combinations of one or more NK₂ receptor antagonists can also be administered.

Please replace the paragraph at page 9, lines 15-21, with the following amended paragraph:

A number of suitable NK₃ receptor antagonists are currently in clinical trials for other indications. These include, without limitation: SB-223412-A or talnetant hydrochloride (((S)-(-)-N-(α -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide hydrochloride) (CAS 204519-66-4) which is available from GlaxoSmithKline, and SR 142801 or osanetant (N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide) (CAS 160492-56-8) which is available from Sanofi-Synthelabo, as well as pharmaceutically acceptable salts thereof. Suitable salts can be prepared according to known techniques. Combinations of one or more NK₃ receptor antagonists can also be administered.